drugset / Trial / NCT02503345
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of different doses of ALLN 177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and recurrent kidney stones.
Timeline
- Start
- 2015-07
- Primary completion
- 2016-08
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Reloxaliase | Protein / enzyme biologic | 1500 iu | Oral |
| Subject | Reloxaliase | Protein / enzyme biologic | 3000 iu | Oral |
| Subject | Reloxaliase | Protein / enzyme biologic | 7500 iu | Oral |